Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Mehner, Christine, Oberg, Ann L., Kalli, Kimberly R., Nassar, Aziza, Hockla, Alexandra, Pendlebury, Devon, Cichon, Magdalena A., Goergen, Krista M., Maurer, Matthew J., Goode, Ellen L., Keeney, Gary L., Jatoi, Aminah, Sahin-Tóth, Miklós, Copland, John A., Radisky, Derek C., Radisky, Evette S.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742138/
https://ncbi.nlm.nih.gov/pubmed/26437224
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires